OLFM2

Across TCGA pan-cancer cohorts, OLFM2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated OLFM2 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher OLFM2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated OLFM2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

KICH, BLCA, and UCEC are the cancer types where OLFM2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
BLCA	DFS	Median	IV	0.095	0.472	<.001	12	view →
UCEC	DFS	Median	All	1.000	0.625	.011	10	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	OS	Median	All	0.189	0.672	.010	6	view →
SKCM	OS	Median	All	0.780	0.308	.017	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

OLFM2–KICH (DFS)

Open the KICH breakdown →